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Diagnosis and management of transient ischaemic
attack and ischaemic stroke in the acute phase
K S McArthur clinical research fellow, T J Quinn lecturer in geriatric medicine, J Dawson lecturer in
clinical pharmacology and stroke, M R Walters professor of clinical pharmacology and stroke
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow G116NT, UK
The care of people with acute ischaemic stroke has improved
dramatically in recent years. Both stroke and transient ischaemic
attack (TIA) are now recognised as medical emergencies that
must be treated with the same urgency as myocardial infarction.
Treatments such as thrombolysis are now widely adopted and
underpinned by a robust evidence base. Rapid and accurate
recognition of cerebral ischaemia, prompt treatment, and referral
to specialist services can reduce the risk of further events.
Although cautious optimism has replaced therapeutic nihilism,
stroke remains an important cause of death and disability and
improvements in stroke services are still sorely needed. There
are an estimated 900 000 stroke survivors in England, half of
whom are dependent on others for care at an estimated cost of
£8bn per year (about €9bn or $13bn).1 This burden will increase
as population demographics change. We review the diagnosis
and acute management of cerebral ischaemia drawing on
evidence from original research (particularly multicentre
randomised clinical trials), registry data, and systematic review
and meta-analysis, and with particular attention to national and
international clinical guidelines. Further discussion of the
epidemiology and economical aspects of contemporary stroke
care are available elsewhere1 2w1; the management of
intracerebral haemorrhage was reviewed in a previous BMJ
article (2009;339:b2586) and is not discussed here. We will
review care in hospital, rehabilitation, and secondary prevention
of stroke in a second paper.
What is an acute cerebrovascular event?
The World Health Organization defines stroke as the sudden
onset of focal neurological signs, of presumed vascular origin,
lasting longer than 24 hours or causing death. It can be further
classified as ischaemic, due to interruption of blood supply, or
haemorrhagic, due to rupture of a cerebral artery. The term
cerebrovascular accident is now discouraged, because there is
nothing “accidental” about cerebrovascular disease. In
recognition of stroke as a medical emergency the term “brain
attack” has been used and seems appropriate. Symptoms of a
TIA are similar to those of stroke but last less than 24 hours.
Indeed, a truly “transient” ischaemic event, with no cerebral
infarction, will usually manifest as a symptom complex lasting
only minutes. Longer events are typically associated with
infarction and should be considered “stroke”; definitions are
likely to change to reflect this.3
Various clinical, radiological, and pathological classification
systems have been proposed to further classify stroke. The
Oxford clinical classification is often used because it is simple
to apply and is of prognostic use.4 It describes four subtypes of
stroke; total anterior circulation stroke (TACS), partial anterior
circulation stroke (PACS), lacunar stroke (LACS), and posterior
circulation stroke (POCS) (box 1).
Once an ischaemic cause is confirmed, the nomenclature can
be altered to convey greater specificityfor example, a partial
anterior circulation infarct (PACI). The underlying cause in
most cerebral ischaemic events is cardioembolic or
atherosclerotic arterial disease, which can cause either in situ
thrombosis or distal embolism. Other causes are much rarer.
Common sources of cardiac emboli are atrial fibrillation, mural
thrombus, and valvular heart disease and these typically involve
the territory of the large intracerebral arteries, particularly the
middle cerebral artery. Atherosclerotic disease typically affects
the extracranial internal carotid artery but also the vertebral and
basilar arteries. Lacunar infarction results from occlusion of
deep perforating arteries, which arise from both the anterior and
posterior circulation, and supply the white matter of the cerebral
hemispheres and brainstem.
Is it an acute cerebrovascular event?
Clinical diagnosis
It is important to rapidly distinguish stroke from one of the
numerous conditions that resemble it (“stroke mimics”, box 2).
In a UK observational study of 350 consecutive suspected stroke
presentations to a teaching hospital at least 30% of referrals
resulted in a non-stroke diagnosis.5 This distinction is important
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Summary points
Education of patients and their relatives to recognise signs of stroke and transient ischaemic attack (TIA) is crucial to
promote early presentation to medical services
TIA and stroke are medical emergencies; refer for urgent specialist opinion
The risk of further cerebrovascular event following TIA is substantial, immediate, quantifiable, and preventable; do not
be reassured by resolution of symptoms
Effective treatments for selected stroke patients include: aspirin within first 48 hours; intravenous thrombolysis; surgical
decompression of cerebral oedema
Admission to a dedicated stroke unit offers mortality and functional benefits to all patients with stroke
Deranged physiology is common in acute stroke and associated with poor prognosis
Sources and selection criteria
The review is based on the authors’ clinical and research experience and informed by a search of published literature.
Electronic databases (Medline and Embase) were searched from inception to December 2010 inclusive, using truncated
keywords: “transient ischaemic attack”; “thrombolytic”; “stroke or cerebrovascular”. In addition, key reference works; national
and international guidelines; and key journals were searched for relevant papers. Particular attention was given to large
randomised controlled trials, systematic reviews, and meta-analyses. The intention was not to offer a comprehensive
systematic review, rather to give a narrative overview and critique of published literature.
Box 1: Oxford system of stroke classification4
Total anterior circulation stroke (TACS)
All three of:
• Contralateral motor or sensory deficit
• Homonymous hemianopia
• Higher cortical dysfunction*
Partial anterior circulation stroke (PACS)
Two of:
• Contralateral motor or sensory deficit
• Homonymous hemianopia
• Higher cortical dysfunction
Posterior circulation stroke (POCS)
Any one of:
• Isolated homonymous hemianopia
• Brain stem signs
• Cerebellar ataxia
Lacunar stroke (LACS)
Any one of:
• Pure motor deficit
• Pure sensory deficit
• Sensorimotor deficit
*Higher cortical dysfunction includes dysphasia/visiospatial disturbance.
to allow evidence based treatment to be started early and to refer
alternative conditions to the appropriate team. It may be useful
to consider the definition of stroke “sudden onset, focal
neurology, of presumed vascular cause”. Thus, for patients with
gradual onset of symptoms, who have no focal symptoms (such
as those who have lost consciousness), or who give a history
that suggests a non-vascular basis for the episode (seizure,
migraine), stroke can probably be excluded, albeit with a few
exceptions.
Formal assessment tools are available to facilitate diagnosis and
are based on these simple principles. Box 3 outlines two tools
commonly used in routine practice. The Face Arm Speech Test
(FAST) is suitable for use by the general public and has a
positive predictive value of 78% (95% confidence interval 72
to 84) for stroke6 while the ROSIER scale, designed for
emergency department use, functions similarly well and includes
a screen for common strokemimics (but can still be administered
in less than five minutes7). Similar tools are available for the
diagnosis of TIA but have yet to be widely adopted.8
Imaging
Brain imaging is indicated to help confirm the diagnosis, identify
the causes, and help initiation of evidence based treatment. The
usual imaging modality is non-contrast computed tomography
(CT) and this remains useful particularly in excluding
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Box 2 Frequency of common conditions that mimic stroke5
Seizure 21%
Sepsis 13%
Toxic/metabolic 11%
Space occupying lesion 9%
Syncope 9%
Delirium 7%
Vestibular 7%
Mononeuropathy 6%
Functional 6%
Dementia 4%
Migraine 3%
Spinal cord lesion 3%
Other 3%
Box 3: Clinometric properties of tools to aid recognition and diagnosis of a cerebrovascular event34
Recognition of Stroke in Emergency Room (ROSIER) scale
• Loss of consciousness or syncope? Yes: −1 point
• Seizure activity? Yes: −1 point
• New acute onset:
Asymmetric facial weakness? Yes: +1 point
Asymmetric arm weakness? Yes: +1 point
Asymmetric leg weakness? Yes: +1 point
Speech disturbance? Yes: +1 point
Visual field defect? Yes: +1 point
• Total −2 to +5
• Stroke likely if score >0 in the absence of hypoglycaemia
• Sensitivity for stroke diagnosis 82%
• Specificity for stroke diagnosis 42%
The Fast Arm Speech Test (FAST) scale
• Facial asymmetry? Yes: +1 point
• Arm (or leg) weakness? Yes: +1 point
• Speech disturbance? Yes: +1 point
• Total 0 to 3
• Suspect stroke if score >0
• Sensitivity for stroke diagnosis 82%
• Specificity for stroke diagnosis 37%
For comparison, diagnosis of stroke by clinical staff’s first impression had sensitivity 77% and specificity 58%.
intracerebral haemorrhage and important mimics such as brain
metastasis. However, sensitivity for detection of ischaemia is
low in the very early stages of stroke and differentiating
ischaemic from haemorrhagic strokes can be difficult on CT
after a period of several days. More advanced CT imaging
techniques such as CT perfusion and angiography are available
and are likely to be used in the future to help better select
patients for some of the acute treatments discussed below. At
present, however, magnetic resonance imaging (MRI) is the
modality of choice. In a study of 217 sequential acute stroke
patients who underwent imaging using both non-contrast CT
and MRI, CT demonstrated sensitivity of 26% (95% CI 20% to
32%) compared with 83% (78% to 88%) for MRI in the
detection of early ischaemia. Further, concerns that MRI may
not detect intracerebral haemorrhage or proves impractical for
“emergency” imaging were not supported.w2
Imaging of the extracranial carotid arteries is required for
patients with anterior circulation stroke. Carotid endarterectomy
is of proved benefit for those with at least moderate carotid
stenosis ipsilateral to an ischaemic stroke in the carotid artery
(?).9 10 This procedure should be performed early; further details
on patient selection will be discussed in a future review. Carotid
duplex ultrasonography is well tolerated and non-invasive but
substantial interobserver variability limits its accuracy.w3 Most
surgical teams will require corroborative imaging, often with
CT or MR angiography, before surgical intervention and many
specialist centres use these as modalities of choice.
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Other investigations
Electrocardiogram abnormalities may suggest a cardiac origin
for thrombus. Where brain imaging and clinical presentation fit
with embolic stroke, or where clinical findings suggest cardiac
disease, cardiac imaging and more detailed telemetry are
indicated. Routine screening for vasculitides or thrombophilia
is not justified.
How should I approach suspected TIA?
Remember that all patients who have ongoing symptoms,
however mild, are considered to have had stroke and urgent
transfer to hospital should be arranged. Where symptoms have
resolved before presentation urgent hospital transfer may not
be required but rapid assessment and treatment if TIA has
occurred is mandatory.
A substantial risk of stroke exists in the early period after TIA.
The magnitude of risk is greater and the time to event shorter
than previously recognised. A recent systematic review reported
an overall 7 day stroke risk of 5.2% after TIA.11
Simple stratification scores can be used to better estimate a
patient’s individual risk. The most commonly used (and best
validated) tool is the ABCD2 score12 (table 1). ABCD2 estimates
risk of recurrence at two days from 1% for patients with “low
risk” to 8.1% for those patients with “high risk”. ABCD2 scoring
is recommended in UK national guidelines and many centres
offer same day assessment of patients at highest risk of stroke.
ABCD2 may also be useful in diagnosis. Single centre registry
data (3646 patients) showed that few referrals with an ABCD2
score of 0 were subsequently found to have a cerebrovascular
diagnosis.13
The fact that the increased risk occurs so soon after TIA tells
us that same day assessment should be the aim for patients with
TIA, although the practicalities of referral and investigation of
stroke will vary according to the local facilities available. UK
guidelines (National Institute for Health and Clinical Excellence
and Scottish Intercollegiate Guidelines Network)14 15 suggest
starting all patients on antiplatelet treatment (aspirin 300 mg)
and referring them for urgent specialist assessment. NICE
recommends that patients with ABCD2 scores greater than 4 be
assessed within 24 hours. Delivery of these targets on a
nationwide and fully inclusive basis will require substantial
investment in services.
The landmark EXPRESS study compared stroke events in
Oxford, UK, before and after a move from their standard to an
immediate access, comprehensive, TIA assessment service.16
An 80% reduction in recurrent stroke at 90 days was
demonstrated with no increase in adverse events (fig 1).
Although we extrapolate these results from a single centre with
caution, it is worth noting that if outcomes were replicated across
all UK stroke centres 10 000 stroke events could be prevented
annually.
How will specialist services manage the
patient with suspected stroke or TIA?
The aim of specialist stroke assessment is confirmation of stroke
diagnosis, identification of the causes, and timely initiation of
evidence based treatment.
Brain imaging should be performed with minimal delay to
distinguish ischaemic from haemorrhagic stroke. Even when
the patient is not eligible for thrombolysis, imaging within 24
hours (although ideally as soon as possible) is the most cost
effective strategy. The need for imaging in transient ischaemic
attack is more contentious. In our unit we routinely scan anyone
with symptoms lasting more than one hour before starting
secondary prevention.
Patients with TIA
Treatments are aimed at preventing a further event, similar to
the secondary treatments given to patients following acute
stroke. In those with confirmed atrial fibrillation or mural
thrombus anticoagulants are warranted. Antiplatelet or
anticoagulant drugs may be considered in all patients, as may
lipid lowering therapy, antihypertensive therapy, carotid surgery,
treatment of diabetes, and advice about diet, lifestyle, and
smoking cessation. A recent focus of research has been the
potential benefits of early antiplatelets, statins, and
antihypertensives. The marked reduction in stroke rate seen in
EXPRESS may have been caused by immediate delivery of
these therapies (patients were givenmedication at clinic review).
We await results of ongoing trials, although emergent stroke
data suggest that “acute” prescription of antihypertensives may
have no clinical benefit.17
Patients with acute ischaemic stroke
Within the first hours to days, proved treatments for acute
ischaemic stroke include admission to a dedicated stroke unit;
administration of intravenous tissue plasminogen activator
(rt-PA); antiplatelet agents; and surgical decompression of
massive cerebral oedema (table 2).
Aspirin
A systematic review of antiplatelets after ischaemic stroke (n=43
041) demonstrated that for every 1000 patients treated acutely
with aspirin (160-300 mg) 13 fewer deaths occurred by the end
of follow-up, which is a modest but important effect at a
population level.18UK guidelines recommend that patients with
acute ischaemic stroke are prescribed aspirin 300 mg daily for
two weeks, followed by a long term secondary preventative
antiplatelet strategy.14 15Aspirin should be withheld for 24 hours
after thrombolysis. Where a patient’s swallowing is impaired
to a degree that precludes oral administration, rectal preparations
may be used. In patients unable to take aspirin, alternatives such
as clopidogrel may be used. There is no evidence to support the
use of early anticoagulation as a treatment for acute ischaemic
stroke.19
Thrombolysis
Intravenous tissue plasminogen activator (rt-PA) alteplase is
beneficial if given within 4.5 hours of acute ischaemic stroke
in selected patients. In Europe, rt-PA is licensed for the treatment
of acute ischaemic stroke provided it is administered within
three hours of symptom onset, but many centres will administer
it up to 4.5 hours based on evidence.20 The benefits of rt-PA are
in reducing longer term disability and not in improved survival
or in immediate improvement in neurological impairment
(although anecdotally this has been observed). Two recent
pooled meta-analyses of the major thrombolysis trials (n=277521
and n=367022) have demonstrated clear benefit of thrombolysis
with significantly better outcomes seen with early treatment
(table 3) In the larger analysis the odds ratios of a favourable
outcome with rt-PA were 2.55 (95% CI 1.44 to 4.52) for 0-90
minutes, 1.64 (1.12 to 2.4) for 91-180 minutes, 1.34 (1.06 to
1.68) for 181-270 minutes, and 1.22 (0.92 to 1.61) for 271-360
minutes in favour of the rt-PA group.22 Trials have reported that
mortality rates at three months are equivalent to placebo.
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The limited time window for delivery of thrombolytic therapy
is a major barrier to its delivery. The risk:benefit ratio beyond
4.5 hours has not been fully established and ongoing clinical
trials aim to provide further evidence. Patients older than 80
years were excluded from most of the clinical trials.
Non-randomised observational data suggest that their risk:benefit
ratio is similar to that of other patients23 (fig 2) and many centres
will give thrombolysis to selected older patients. However, data
from randomised studies are lacking and we await results of the
third international stroke trial.w4.
Many clinicians fear the potential for iatrogenic intracerebral
haemorrhage after thrombolysis and patient selection guidance
is designed to minimise this risk. A list of contraindications to
thrombolysis is shown in table 4. For many of these, as we have
gainedmore experience with thrombolysis, conditions that were
previously “absolute” contraindications to rt-PA are now deemed
“relative” contraindications. Because this is an evolving
landscape, we advise referral of all hyperacute suspected strokes
to a specialist team unless there is substantial premorbid
disability. As the benefits of rt-PA are in reducing disability,
this approach is not routinely used in patients who are already
functionally impaired.
The Safe Implementation of Thrombolysis in Stroke-Monitoring
Study (SITS-MOST) registry of clinical practice was conducted
in accordance with the terms of the restricted European licence
for alteplase use and has helped to assuage some concerns about
the potential for iatrogenic intracerebral haemorrhage.24 Across
285 European centres (and 6483 patients), rates of “good”
outcome (independence) were comparable or improved
compared to those seen in clinical trials and likewise for rates
of haemorrhagic transformation. Importantly, outcomes were
similar regardless of levels of experience of the centre.
Provision of a comprehensive thrombolysis service demands
substantial economic investment and infrastructural change.
Despite endorsement by guideline and national targets,
geographical disparity in availability and use of rt-PA are
apparent within the UK and internationally. In an era of
increasing financial scrutiny it is reassuring that the (limited)
economic data on use of rt-PA suggest overall cost benefit,
driven by prevention of longer term disability.25
Surgical intervention
“Malignant” swelling of an infarcted cerebral hemisphere can
arise in the days following occlusion of the carotid or middle
cerebral artery, and although uncommon it is associated with a
very high mortality.26However, surgical intervention saves lives
and reduces disability in selected patients younger than 60. In
this group, meta-analysis of three randomised controlled trials
showed superiority of surgical craniotomy compared to standard
medical care with a number needed to treat of two to reduce
disability.26 Reducing mortality at the expense of substantial
disability remains a possibility and improved data on selecting
patients for surgery are urgently needed.
Physiological monitoring and other
treatments
Failure of homoeostasic mechanisms during the acute phase of
stroke is common and supportive care delivered through a
specialist stroke unit is crucial. However, evidence to support
taking measures to “correct” deranged physiology is lacking;
even simple interventions such as supplementary hydration and
oxygen therapy are of unproved benefit and are currently being
investigated. Regular observation of level of consciousness is
useful as change in Glasgow coma scale can herald potentially
treatable complications such as development of cerebral oedema
or haemorrhage.
The role of blood pressure control in the immediate phase after
stroke is unclear. Arterial hypertension is found in 80% of
patients following acute stroke and is associated with a poor
outcome.27 The ACCESS study suggested that early use of
angiotensin receptor blockade was safe in acute ischaemic
stroke;28 however, recent publication of a larger phase III
efficacy trial (SCAST) has demonstrated no benefit and a
suggestion of increased harm.29 Routine lowering of blood
pressure is not recommended in UK or international guidelines.
Treatment may be appropriate in specific circumstances such
as hypertensive encephalopathy or aortic dissection; however,
guidance on agent to use and target blood pressure varies across
guidelines.
A meta-analysis of observational studies showed that the acute
phase of stroke carries a high risk of infection and pyrexia is
associated with a poor outcome, possibly because of adverse
effects on free radical production or intracerebral metabolism.30
Limited data support the use of anti-pyretic medication and
cooling31 but no adequately powered randomised trial has
investigated their benefits. Standard treatment of pyrexia is
recommended and should prompt an assessment for a possible
underlying source of sepsis.
Raised blood glucose is also common in the acute phase after
ischaemic stroke, often in the absence of pre-existing diabetes,
which may represent a stress response. Despite its association
with increased mortality and poor functional outcome,32 the
largest randomised controlled trial of blood glucose reduction
in stroke reported no benefit of insulin infusion compared with
placebo;33 although some have argued that the study was
underpowered to detect a true effect. Lowering of abnormally
high blood glucose (>11 mmol/L) with titrated insulin remains
common practice to maintain normoglycaemia. Aggressive
treatment of hyperglycaemia in critically ill patients was found
to increase mortality in the NICE SUGAR study.w5 Although
this study was not specific to stroke patients, we must be
cautious in the use of intravenous insulin in any severely unwell
group of patients.
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Tables
Table 1| ABCD2 score and risk of stroke12
Risk of strokeABCD2score
7 days2 days
Characteristic
––1 pointAge ≥60 years
––1 pointBlood pressure ≥140/90 mm Hg
Clinical features
––2 pointsFocal weakness
––1 pointSpeech disturbance without weakness
Duration
––2 points≥60 minutes
––1 point1-59 minutes
––1 pointDiabetes
Total ABCD2 score
1.2%1%<4 pointsLow risk
5.9%4.1%4-5 pointsModerate risk
11.7%8.1%>5 pointsHigh risk
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Table 2| Effective treatments for stroke
Surgeryrt-PAStroke unitAspirin
21020100Number needed to treat
5%†10%*100%70-80%Proportion eligible
*Based on UK data; some European centres have achieved far higher rates of thrombolysis within licence.
†Based on European data; values vary depending on demographics (particularly age) of population served.
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Table 3| Benefit of rt-PA treatment at 90 days22
Estimated number needed to treat for favourable outcomeOdds ratio in favour of favourable outcome (95% CI)Time between event and treatment
4.52.55 (1.44 to 4.52)0-90 minutes
9.01.64 (1.12 to 2.40)91-180 minutes
14.11.34 (1.06 to 1.68)181-270 minutes
21.41.22 (0.92 to 1.61)271-360 minutes
Favourable outcome defined as modified Rankin score of 0-1 at 90 days.
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Table 4| Contraindications to use of rt-PA in acute ischaemic stroke
Specific contraindications to use in ischaemic strokeGeneral contraindications to any use of rt-PA
Evidence of intracranial haemorrhageSevere bleeding within past six months
Onset of symptoms >4.5 hoursKnown bleeding diathesis
Unclear time of onsetOral anticoagulant use (INR >1.4)
Age <18 or >80 yearsHistory of intracranial haemorrhage
Mild stroke (NIHSS <5) or rapid improvementRecent (<10 days) cardiopulmonary resuscitation
Severe stroke (NIHSS >25 or imaging)Bacterial endocarditis or pericarditis
Seizure at onset of strokeAcute pancreatitis
Symptoms indicating subarachnoid haemorrhageRecent (<3 months) peptic ulcer disease
Platelet count < 100 ×106/LNeoplasm with bleeding risk
Heparin within last 48 hours with raised PTTRecent puncture of non-compressible vessel
Previous stroke within past three monthsMajor surgery or trauma (<3 months)
Previous stroke and concomitant diabetesSevere liver disease
Systolic BP >185 mm Hg or diastolic BP >110 mm HgRecent obstetric delivery
INR=international normalised ratio, NIHSS=National Institute of Health Stroke Scale, PTT: prothrombin time, BP=blood pressure.
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Figures
Fig1 EXPRESS study protocol16
Shift towards better outcomes on modified Rankin scale at three months adjusted for age and baseline severity (defined
by National Institutes of Stroke scale)23
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